This is a Phase IV, pilot, open-label, national, multi-centric study planned to determine the
gene expression profiles and histologic changes of the endometrial tissue before and after
stimulation with Gonal-f®. Physicians are interested in identifying predictive genetic
markers in assisted reproductive technologies (ART) in addition to the clinical predictive
factors already known. Among those predictive factors, the state of the endometrium is
considered as an important implantation determining factor for which pharmacogenomic research
is of great interest.
The direct benefits of this study will be to know whether the endometrial gene expression
profile is modified in response to stimulation treatment and have an impact or not on the
endometrial tissue receptivity. The potential benefits of this study could be to assess the
therapy optimization based on individual treatment response and gene expression profile
compared to group treatment response in infertile women and prediction of response to therapy
based on gene expression profiling before and after Gonal-f® stimulation in infertile women.